Submitted by Anjali Fortna on Tue, 05/26/2015 - 2:43pm Currently, how confident are you in your: * Please use the scale: 1=NOT at all confident, 2=Not very confident, 3=Somewhat confident, 4=Confident, 5=Extremely confident, 12345 Ability to identify and address treatment barriers when managing patients with multiple sclerosis? Ability to identify and address treatment barriers when managing patients with multiple sclerosis? - 1 Ability to identify and address treatment barriers when managing patients with multiple sclerosis? - 2 Ability to identify and address treatment barriers when managing patients with multiple sclerosis? - 3 Ability to identify and address treatment barriers when managing patients with multiple sclerosis? - 4 Ability to identify and address treatment barriers when managing patients with multiple sclerosis? - 5 Understanding of the science of B-cell targeted therapy in multiple sclerosis? Understanding of the science of B-cell targeted therapy in multiple sclerosis? - 1 Understanding of the science of B-cell targeted therapy in multiple sclerosis? - 2 Understanding of the science of B-cell targeted therapy in multiple sclerosis? - 3 Understanding of the science of B-cell targeted therapy in multiple sclerosis? - 4 Understanding of the science of B-cell targeted therapy in multiple sclerosis? - 5 The OPERA study results showed a 95% decrease in MRI lesion activity in which therapeutic option? * Interferon-beta-1a Ocrelizumab Rituximab S1P1 modulator According to a recent study, which of the following therapeutic options reduces the relative risk of MS in patients experiencing their first clinical demyelinating event by 44.6%? * Ocrelizumab Fingolimod Rituximab Minocycline True or False: Due to increased incidence of MS occurring so quickly, research suggests that the risk factors have to be environmental, in addition to genetic. * True False There was a study conducted that compared patients that discontinued use of their DMT after being stable without relapses in a 5-year period and a group of patients who remained on their DMT. Which of the following statements is false regarding the results of this study? * There was an equal amount of relapses between DMT stoppers and DMT stayers Disability was significantly increased in DMT stoppers than DMT stayers There was no significant difference in disability Both A and C A paper presented at ECTRIMS 2015, titled, “Effect of MD1003 (High-dose Biotin) in Progressive Multiple Sclerosis: Subgroup Analyses of the MS-SPI Trial”, showed that patients in what subset of the EDSS spectrum had a better response to biotin? * Patients who were under 2.5 Patients who were between 2.5 and 4.5 Patients who were between 4.5 and 5.5 Patients who were 6.0 and greater Which of the following is an indicator of higher risk of PML in patients on natalizumab? * Patients that have been on the therapy for more than two years PML virus detected by an assay Prior intake of immunosuppressive drug All of the above One study presented at ECTRIMS 2015 suggested there is a discrepancy between risk viewed by the physician vs risk viewed by the patient regarding their MS treatment. According to this research, if a patient felt there was a treatment that might improve their MS or keep it in control, what was their perceived risk likely to be? * The patients were more likely to be willing to take a high risk for a perceived benefit The patients were not anymore likely to be willing to take a high risk for a perceived benefit The patients were more unlikely to be willing to take a high risk for a perceived benefit The patient is likely to go with their doctors recommendation regardless of the risk or perceived benefit Please take a moment to reflect on your current use of the practice strategies discussed in this activity. You will not be graded on your responses. Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with multiple sclerosis. * Please use the scale: 1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, N/A=Not applicable to me 12345N/A Communicate treatment barriers to patients and develop personalized treatment plans. Communicate treatment barriers to patients and develop personalized treatment plans. - 1 Communicate treatment barriers to patients and develop personalized treatment plans. - 2 Communicate treatment barriers to patients and develop personalized treatment plans. - 3 Communicate treatment barriers to patients and develop personalized treatment plans. - 4 Communicate treatment barriers to patients and develop personalized treatment plans. - 5 Communicate treatment barriers to patients and develop personalized treatment plans. - N/A Understand the neurodegenerative and inflammatory process of MS, as well as emerging therapeutic options, such as B-cell targeted therapies. Understand the neurodegenerative and inflammatory process of MS, as well as emerging therapeutic options, such as B-cell targeted therapies. - 1 Understand the neurodegenerative and inflammatory process of MS, as well as emerging therapeutic options, such as B-cell targeted therapies. - 2 Understand the neurodegenerative and inflammatory process of MS, as well as emerging therapeutic options, such as B-cell targeted therapies. - 3 Understand the neurodegenerative and inflammatory process of MS, as well as emerging therapeutic options, such as B-cell targeted therapies. - 4 Understand the neurodegenerative and inflammatory process of MS, as well as emerging therapeutic options, such as B-cell targeted therapies. - 5 Understand the neurodegenerative and inflammatory process of MS, as well as emerging therapeutic options, such as B-cell targeted therapies. - N/A Leave this field blank
